Tubulis GmbH’s Post

IQVIA Institute’s latest report on Hematologic Cancer Opportunities for Patient Equality highlights the variability in country-level prioritization of certain types of novel medicines for a variety of cancers. For example, Central and Eastern European countries tend to have lower utilization of hematological medicines though all have similar defined daily doses (DDD) per capita in 2023, ranging from 37% to 44% below the European average. What’s driving these variances and inequities? Download the Hematologic Cancer Opportunities for Patient Equality (HOPE) report to find out: https://bit.ly/3xz5ETw. #Oncology #PharmaSpending

Theories behind Bacillus Calmette-Guérin failure in high-risk non-muscle-invasive bladder cancer and update on current management. This #CancerPathogenesisAndTherapy review discusses how #BCGtherapy continues to be a gold-standard for #BladderCancer treatment, potential theories behind #BCG failure, and approaches to better #patient selection and non-invasive treatments. More here: https://lnkd.in/g5f43N5w .

A new study presented at the 2024 ASCO Annual Meeting shows that trastuzumab deruxtecan outperforms standard chemotherapy in delaying cancer progression for HR+, HER2-low, and HER2-ultralow metastatic breast cancer patients. #ASCO24 #BreastCancer #TrastuzumabDeruxtecan

A new study presented at the 2024 ASCO Annual Meeting shows that trastuzumab deruxtecan outperforms standard chemotherapy in delaying cancer progression for HR+, HER2-low, and HER2-ultralow metastatic breast cancer patients. #ASCO24 #BreastCancer #TrastuzumabDeruxtecan

March is Colorectal Cancer Awareness Month. Unlike most cancers, colorectal cancer is often preventable with screening and is highly treatable when detected early. At Clearway Health, we support those impacted by colorectal cancer. We're dedicated to raising awareness about the importance of early detection and treatment and we emphasize the crucial role of specialty pharmacy drugs in improving and saving lives. Learn more at https://ow.ly/Ajpw50QGSJB #colorectalcancerawareness #earlydetectionsaveslives #specialtypharmacy #clearwayhealth

The International Bladder Cancer Group (IBCG) considers a complete response rate (for carcinoma in situ) or recurrence-free rate (for papillary tumours) of at least 50% at 6 months, 30% at 12 months and 25% at 18 months as clinically meaningful.   While it has been argued that novel therapies with these efficacies would not be real competitors to radical cystectomy, this approach fails to take into account that: ▶ Bladder cancer occurs more frequently in the elderly, in whom morbidity and mortality from cystectomy are significant factor. In these patients, potential cure is not the only consideration, and it is precisely this group that requires alternative treatments. ▶ The lack of cystectomies for failures in the pembrolizumab and nadofaragene trials indicates that many patients are unable or unwilling to undergo cystectomy.   More tomorrow!   #medicalinnovation #bladdercancer #HIVECHEAT #HIVEC #CombatMedical

📣NEW: Breast cancer drug repurposed for infant with congenital hyperinsulinism in pilot study. A 4-month-old with congenital hyperinsulinism responded well to off-label treatment with a breast cancer drug, researchers reported. Daily treatment of alpelisib (Piqray) substantially reduced hypoglycemia over 13 weeks. Khalid Hussain, MBChB, MD, MSc, explains that "One of the major side effects of this medication is high blood glucose levels, so [we] leveraged this observation to treat severe hypoglycemia." To read more about this exciting development, visit https://bit.ly/3OixRn0 #hyperinsulinism #raredisease #congenitalhyperinsulinism #hypoglycemia | Hyperinsulinism | Congenital | HI | Hypoglycemia | Rare Disease

The approval of #toripalimab (#LOQTORZ, Coherus BioSciences) for the treatment of #nasopharyngeal carcinoma marks a significant milestone in the management of this type of cancer, as toripalimab is the first approved PD-1 inhibitor for patients with treatment-naive or recurrent nasopharyngeal carcinoma.  The JUPITER-02 trial results solidify the toripalimab combination as a new standard of care in this patient population. The 3-year OS rate was 65.1% in the combination arm, with a median PFS of 21.4 months compared with 8.2 months with chemotherapy alone. The approval of toripalimab has significant implications for the management of nasopharyngeal carcinoma, as it provides a new treatment option for patients with recurrent or metastatic disease.

Early detection of cancer can significantly improve treatment outcomes. Regular screenings, depending on your age, gender, and risk factors, can help detect cancer in its early stages. Common screening methods include mammograms for breast cancer, colonoscopies for colorectal cancer, Pap smears for cervical cancer, and prostate-specific antigen (PSA) tests for prostate cancer. Be vigilant about any changes in your body, such as lumps, persistent pain, unusual bleeding, or changes in bowel or bladder habits. If you notice any concerning symptoms, it's essential to see a healthcare professional promptly.

WATCH: A panel of experts in gynecologic oncology explore advancements in the treatment of endometrial and #CervicalCancers, including breaking clinical trial data from #ESMO23, and their potential impact on clinical practice. #oncology https://lnkd.in/egcWfj34